Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Hyperthyroidism | Research

Association between thymic hyperplasia and serum calcium level in Graves’ disease

Authors: Jing Zeng, Lan Li, Dong Wei

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Background

Graves' disease increases bone resorption in hyperthyroidism, leading to elevated serum calcium levels and a negative bone balance. Thymic hyperplasia is observed in some Graves' disease patients. What's more, there have been a few reports of increased serum calcium and severe osteoporosis induced by Graves’ disease with thymic hyperplasia. It remains unclear whether Graves’ disease with thymic hyperplasia is associated with higher serum calcium levels. Our study aimed to investigate the possibility of elevated serum calcium levels and aggravated bone mobilization in Graves’ disease patients with thymic hyperplasia.

Methods

Newly diagnosed and untreated patients with Graves' disease (n = 96) were enrolled. They were divided into two groups based on the incidental detection of thymic hyperplasia during imaging. Albumin, alkaline phosphatase, calcium, free triiodothyronine, free thyroxine, thyroid-stimulating hormone, and thyrotrophin receptor antibody (TRAb) were measured, and a computerized tomography of the chest was obtained.

Results

Patients with Graves’ disease who had thymic hyperplasia were notably younger (P=0.018) and exhibited higher serum calcium levels (P=0.001) compared to those with Graves’ disease without thymic hyperplasia. In the multiple regression analysis, thymic hyperplasia, TRAb, and female gender were significant variables associated with elevated serum calcium levels in patients with Graves' disease, collectively accounting for 31.7% of the variation in serum calcium.

Conclusions

Graves’ disease patients with thymic hyperplasia showed higher serum calcium levels. thymic hyperplasia, TRAb, and female gender were found to be correlated with increased serum calcium levels in Graves’ disease, suggesting a potential association between thymic hyperplasia and bone mobilization in Graves’ disease.
Literature
1.
go back to reference Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM & Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018; 14: 301-316. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM & Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018; 14: 301-316.
2.
go back to reference Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229:415–20.CrossRefPubMed Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229:415–20.CrossRefPubMed
3.
go back to reference Inaba M, Hamada N, Itoh K, Mimura T, Ohno M, Yamakawa J, Ikeda S, Okamoto T, Morii H, Wada M. A case report on disequilibrium hypercalcemia in hyperthyroidism. Comparison of calcium metabolism with other patients with hyperthyroidism. Endocrinol Jpn. 1982;29:389–93.CrossRefPubMed Inaba M, Hamada N, Itoh K, Mimura T, Ohno M, Yamakawa J, Ikeda S, Okamoto T, Morii H, Wada M. A case report on disequilibrium hypercalcemia in hyperthyroidism. Comparison of calcium metabolism with other patients with hyperthyroidism. Endocrinol Jpn. 1982;29:389–93.CrossRefPubMed
4.
go back to reference Gogakos AI, Duncan Bassett JH, Williams GR. Thyroid and bone. Arch Biochem Biophys. 2010;1:129–36.CrossRef Gogakos AI, Duncan Bassett JH, Williams GR. Thyroid and bone. Arch Biochem Biophys. 2010;1:129–36.CrossRef
6.
go back to reference Murakami M, Hosoi Y, Negishi T, Kamiya Y, Miyashita K, Yamada M, Iriuchijima T, Yokoo H, Yoshida I, Tsushima Y, Mori M. Thymic hyperplasia in patients with Graves’ disease. Identification of thyrotropin receptors in human thymus. J Clin Invest. 1996;98:2228–34.CrossRefPubMedPubMedCentral Murakami M, Hosoi Y, Negishi T, Kamiya Y, Miyashita K, Yamada M, Iriuchijima T, Yokoo H, Yoshida I, Tsushima Y, Mori M. Thymic hyperplasia in patients with Graves’ disease. Identification of thyrotropin receptors in human thymus. J Clin Invest. 1996;98:2228–34.CrossRefPubMedPubMedCentral
7.
go back to reference Jinguji M, Nakajo M, Nakajo M, Koriyama C, Yoshiura T. Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb. J Endocr Soc. 2017;1:852–60.PubMedPubMedCentral Jinguji M, Nakajo M, Nakajo M, Koriyama C, Yoshiura T. Thymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb. J Endocr Soc. 2017;1:852–60.PubMedPubMedCentral
8.
go back to reference Hamzaoui AA, Klii RR, Salem RR, Kochtali II, Golli MM, Mahjoub SS. Thymic hyperplasia in a patient with Grave’s disease. Int Arch Med. 2012;9:6.CrossRef Hamzaoui AA, Klii RR, Salem RR, Kochtali II, Golli MM, Mahjoub SS. Thymic hyperplasia in a patient with Grave’s disease. Int Arch Med. 2012;9:6.CrossRef
9.
go back to reference Haider Uzma, Richards Patrick, Gianoukakis Andrew G. Thymic Hyperplasia Associated with Graves’ Disease: Pathophysiology and Proposed Management Algorithm. Thyroid. 2017;27:994–1000.CrossRefPubMed Haider Uzma, Richards Patrick, Gianoukakis Andrew G. Thymic Hyperplasia Associated with Graves’ Disease: Pathophysiology and Proposed Management Algorithm. Thyroid. 2017;27:994–1000.CrossRefPubMed
10.
go back to reference Popoveniuc G, Sharma M, Devdhar M, Wexler JA, Carroll NM, Wartofsky L, Burman KD. Graves’ disease and thymic hyperplasia: the relationship of thymic volume to thyroid function. Thyroid. 2010;20:1015–8.CrossRefPubMed Popoveniuc G, Sharma M, Devdhar M, Wexler JA, Carroll NM, Wartofsky L, Burman KD. Graves’ disease and thymic hyperplasia: the relationship of thymic volume to thyroid function. Thyroid. 2010;20:1015–8.CrossRefPubMed
11.
go back to reference Giovanella Luca, Suriano Sergio, Ceriani Luca. Graves’ disease, thymus enlargement, and hypercalcemia. New Engl J Med. 2008;358:1078–9.CrossRefPubMed Giovanella Luca, Suriano Sergio, Ceriani Luca. Graves’ disease, thymus enlargement, and hypercalcemia. New Engl J Med. 2008;358:1078–9.CrossRefPubMed
12.
go back to reference Kamath C, Witczak J, Adlan MA, Premawardhana LD. Managing thymic enlargement in Graves’ disease. Endocrinol Diabetes Metab Case Rep. 2019;31:18–0119. Kamath C, Witczak J, Adlan MA, Premawardhana LD. Managing thymic enlargement in Graves’ disease. Endocrinol Diabetes Metab Case Rep. 2019;31:18–0119.
13.
go back to reference Yan D, Xu Y, Li LX. The coexistence of hypercalcemia, osteoporosis and thymic enlargement in graves’ disease: a case report. BMC Endocr Disord. 2020;30:97.CrossRef Yan D, Xu Y, Li LX. The coexistence of hypercalcemia, osteoporosis and thymic enlargement in graves’ disease: a case report. BMC Endocr Disord. 2020;30:97.CrossRef
14.
go back to reference Akalin A, Colak O, Alatas O, Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol (Oxf). 2002;57:125–9.CrossRefPubMed Akalin A, Colak O, Alatas O, Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol (Oxf). 2002;57:125–9.CrossRefPubMed
15.
go back to reference Diana T, Daiber A, Oelze M, Neumann S, Olivo PD, Kanitz M, Stamm P, Kahaly GJ. Stimulatory TSH-Receptor Antibodies and Oxidative Stress in Graves Disease. J Clin Endocrinol Metab. 2018;103:3668–77.CrossRefPubMedPubMedCentral Diana T, Daiber A, Oelze M, Neumann S, Olivo PD, Kanitz M, Stamm P, Kahaly GJ. Stimulatory TSH-Receptor Antibodies and Oxidative Stress in Graves Disease. J Clin Endocrinol Metab. 2018;103:3668–77.CrossRefPubMedPubMedCentral
16.
go back to reference Halsted WS. Significance of the thymus gland in Graves’ disease. Bull Johns Hopkins Hosp. 1914;25:223–34. Halsted WS. Significance of the thymus gland in Graves’ disease. Bull Johns Hopkins Hosp. 1914;25:223–34.
18.
go back to reference Yacoub A, Gaitonde DY, Wood JC. Thymic hyperplasia and Graves’ disease: management of anterior mediastinal masses in patients with Graves’ disease. Endocr Pract. 2009;15:534–9.CrossRefPubMed Yacoub A, Gaitonde DY, Wood JC. Thymic hyperplasia and Graves’ disease: management of anterior mediastinal masses in patients with Graves’ disease. Endocr Pract. 2009;15:534–9.CrossRefPubMed
19.
go back to reference Kim MJ, Oh SW, Youn H, Na J, Kang KW, Park DJ, Park YJ, Jang JJ, Lee KE, Jung KC, Chung JK. Thyroid-Related Protein Expression in the Human Thymus. Int J Endocrinol. 2017;2017:8159892.CrossRefPubMedPubMedCentral Kim MJ, Oh SW, Youn H, Na J, Kang KW, Park DJ, Park YJ, Jang JJ, Lee KE, Jung KC, Chung JK. Thyroid-Related Protein Expression in the Human Thymus. Int J Endocrinol. 2017;2017:8159892.CrossRefPubMedPubMedCentral
20.
go back to reference Dutton CM, Joba W, Spitzweg C, Heufelder AE, Bahn RS. Thyrotropin receptor expression in adrenal, kidney, and thymus. Thyroid. 1997;7:879–84.CrossRefPubMed Dutton CM, Joba W, Spitzweg C, Heufelder AE, Bahn RS. Thyrotropin receptor expression in adrenal, kidney, and thymus. Thyroid. 1997;7:879–84.CrossRefPubMed
21.
go back to reference Song YS, Won J, Kim MJ, Lee JH, Kim DW, Chung JK, Park do J & Park YJ,. Graves’ patient with thymic expression of thyrotropin receptors and dynamic changes in thymic hyperplasia proportional to Graves’ disease activity. Yonsei Med J. 2016;57:795–8.CrossRefPubMedPubMedCentral Song YS, Won J, Kim MJ, Lee JH, Kim DW, Chung JK, Park do J & Park YJ,. Graves’ patient with thymic expression of thyrotropin receptors and dynamic changes in thymic hyperplasia proportional to Graves’ disease activity. Yonsei Med J. 2016;57:795–8.CrossRefPubMedPubMedCentral
22.
go back to reference Amashukeli M, Korinteli M, Zerekidze T, Jikurauli N, Shanava S, Tsagareli M, Giorgadze E. The negative correlation between thyrotropin receptor-stimulating antibodies and bone mineral density in postmenopausal patients with Graves’ disease. J Investig Med. 2013;61:842–7.CrossRefPubMed Amashukeli M, Korinteli M, Zerekidze T, Jikurauli N, Shanava S, Tsagareli M, Giorgadze E. The negative correlation between thyrotropin receptor-stimulating antibodies and bone mineral density in postmenopausal patients with Graves’ disease. J Investig Med. 2013;61:842–7.CrossRefPubMed
23.
go back to reference Belsing TZ, Tofteng C, Langdahl BL, Charles P, Feldt-Rasmussen U. Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves’ disease? Nutr Metab (Lond). 2010;1:72.CrossRef Belsing TZ, Tofteng C, Langdahl BL, Charles P, Feldt-Rasmussen U. Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves’ disease? Nutr Metab (Lond). 2010;1:72.CrossRef
24.
go back to reference Jodar E, Munoz-Torres M, Escobar-Jimenez F, Quesada-Charneco M, Lund del Castillo JD. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of etiology and menopause. Clin Endocrinol (Oxf). 1997;47:279–85.CrossRefPubMed Jodar E, Munoz-Torres M, Escobar-Jimenez F, Quesada-Charneco M, Lund del Castillo JD. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of etiology and menopause. Clin Endocrinol (Oxf). 1997;47:279–85.CrossRefPubMed
25.
go back to reference Karga H, Papapetrou PD, Korakovouni A, Papandroulaki F, Polymeris A, Pampouras G. Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf). 2004;1:466–72.CrossRef Karga H, Papapetrou PD, Korakovouni A, Papandroulaki F, Polymeris A, Pampouras G. Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf). 2004;1:466–72.CrossRef
26.
go back to reference Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K. Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease. Osteoporos Int. 2006; 17: 1103-10. Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K. Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease. Osteoporos Int. 2006; 17: 1103-10.
27.
go back to reference Arvey CB, O’Shea PJ, Scott AJ, Robson H, Siebler T, Shalet SM, Samarut J, Chassande O, Williams GR. Molecular mechanisms of thyroid hormone effects on bone growth and function. Mol Genet Metab. 2002;75:17–30.CrossRef Arvey CB, O’Shea PJ, Scott AJ, Robson H, Siebler T, Shalet SM, Samarut J, Chassande O, Williams GR. Molecular mechanisms of thyroid hormone effects on bone growth and function. Mol Genet Metab. 2002;75:17–30.CrossRef
28.
go back to reference Campos-Pastor MM, Munoz-Torres M, Escobar-Jimenez F, Ruiz De Almodovar M, Jodar Gimeno E. Bone mass in females with different thyroid disorders: influence of menopausal status. Bone Miner. 1993;21:1–82.CrossRefPubMed Campos-Pastor MM, Munoz-Torres M, Escobar-Jimenez F, Ruiz De Almodovar M, Jodar Gimeno E. Bone mass in females with different thyroid disorders: influence of menopausal status. Bone Miner. 1993;21:1–82.CrossRefPubMed
29.
go back to reference Takedani K, Notsu M, Yamauchi M, Nawata K, Sugimoto T, Kanasaki K. Graves’ disease and vertebral fracture: Possible pathogenic link in postmenopausal women. Clin Endocrinol (Oxf). 2020;93:204–11.CrossRefPubMed Takedani K, Notsu M, Yamauchi M, Nawata K, Sugimoto T, Kanasaki K. Graves’ disease and vertebral fracture: Possible pathogenic link in postmenopausal women. Clin Endocrinol (Oxf). 2020;93:204–11.CrossRefPubMed
30.
go back to reference Cho SW, Bae JH, Noh GW, Kim YA, Moon MK, Park KU, Song J, Yi KH, Park do J, Chung JK, Cho BY, Park YJ. The Presence of Thyroid-Stimulation Blocking Antibody Prevents High Bone Turnover in Untreated Premenopausal Patients with Graves' Disease. PLoS One. 10; 2015: e0144599. Cho SW, Bae JH, Noh GW, Kim YA, Moon MK, Park KU, Song J, Yi KH, Park do J, Chung JK, Cho BY, Park YJ. The Presence of Thyroid-Stimulation Blocking Antibody Prevents High Bone Turnover in Untreated Premenopausal Patients with Graves' Disease. PLoS One. 10; 2015: e0144599.
31.
go back to reference Suh H, Rosen JE, Doherty GM, Saunders BD, McAneny D. Graves’ disease and thymic hyperplasia. Surgery. 2013;154:1473–7.CrossRefPubMed Suh H, Rosen JE, Doherty GM, Saunders BD, McAneny D. Graves’ disease and thymic hyperplasia. Surgery. 2013;154:1473–7.CrossRefPubMed
32.
go back to reference Hassman R, Weetman AP, Gunn C, Stringer BM, WynfordThomas D, Hall R, McGregor AM. The effects of hyperthyroidism on experimental autoimmune thyroiditis in the rat. Endocrinology. 1985;116:1253–8.CrossRefPubMed Hassman R, Weetman AP, Gunn C, Stringer BM, WynfordThomas D, Hall R, McGregor AM. The effects of hyperthyroidism on experimental autoimmune thyroiditis in the rat. Endocrinology. 1985;116:1253–8.CrossRefPubMed
33.
go back to reference Simpson JG, Gray ES, Michie W, Beck JS. The influence of preoperative drug treatment on the extent of hyperplasia of the thymus in primary thyrotoxicosis. Clin Exp Immunol. 1975;22:249–55.PubMedPubMedCentral Simpson JG, Gray ES, Michie W, Beck JS. The influence of preoperative drug treatment on the extent of hyperplasia of the thymus in primary thyrotoxicosis. Clin Exp Immunol. 1975;22:249–55.PubMedPubMedCentral
34.
go back to reference Scheiff JM, Cordier AC, Haumont S. Epithelial cell proliferation in thymic hyperplasia induced by triiodothyronine. Clin Exp Immunol. 1977;27:516–21.PubMedPubMedCentral Scheiff JM, Cordier AC, Haumont S. Epithelial cell proliferation in thymic hyperplasia induced by triiodothyronine. Clin Exp Immunol. 1977;27:516–21.PubMedPubMedCentral
Metadata
Title
Association between thymic hyperplasia and serum calcium level in Graves’ disease
Authors
Jing Zeng
Lan Li
Dong Wei
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-024-01541-4

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.